PureTech Health (PRTC)
NASDAQ:PRTC
Want to see PRTC full AI Analyst Report?
Earnings Data
Report Date
Aug 27, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-1.9Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced meaningful clinical and operational progress with financial conservatism and some near‑term funding dependencies. Highlights include positive Phase Ib data for Gallop (LYT‑200) with dose selection and excellent safety, Celea’s Phase III readiness and substantial fundraising progress, a conservative cash runway to end‑2028, reduced operating loss (~27.6% improvement), continued monetization track record (>$1B historically and ~$125M realized from a royalty sale), and Seaport IPO activity — all indicating execution of the hub‑and‑spoke model. Lowlights are the year‑over‑year decline in cash (≈24.4% from 2024 to 2025 and further to ~$248M by March 31, 2026), a swing to consolidated net loss in 2025 driven by the absence of a prior one‑time gain, very low and flat revenues (~$4.7M), and reliance on external fundraising for key Phase III/registration programs which introduces execution and dilution risk. Overall, the positives around portfolio clinical progress, disciplined cost reduction and clear funding plans for key programs outweigh the financial headwinds, though the company remains dependent on successful external financings and monetizations to realize upside.Company Guidance
Positive Phase Ib Data for Gallop (LYT-200)
Top-line Phase Ib data for LYT-200 in relapsed/refractory high‑risk MDS and AML were positive. Safety profile: no dose‑limiting toxicities or myeloid suppression; dose for next study identified at 12 mg/kg. Management has prioritized relapsed/refractory high‑risk MDS and plans FDA engagement toward a potentially registration‑enabling trial, with third‑party capital expected to fund the program (majority external).
Celea's Deupirfenidone Phase IIb Success and Phase III Readiness
Celea’s deupirfenidone demonstrated robust efficacy in Phase IIb for idiopathic pulmonary fibrosis (IPF) and is Phase III ready. Celea’s fundraising is described as 'substantially complete' (subject to negotiations) with a target close by early Q3 2026 to support the Phase III SURPASS‑IPF trial, which is expected to commence close to close of financing.
Runway Conservatively Extended to End of 2028
PureTech expects operational runway of at least through the end of 2028 based on existing financial assets as of Dec 31, 2025, and this guidance is stated to be conservative and inclusive of planned participation in certain entity fundraisings (Celea and Gallop support assumed).
Improved Operating Loss and Cost Discipline
Operating loss decreased from $136.1M in 2024 to $98.5M in 2025, an improvement of $37.6M (~27.6% reduction). Management attributes this to lower G&A and R&D costs following the deconsolidation of Seaport and an intentional move toward a leaner hub and capital discipline.
Strong Track Record of Monetization and Non‑dilutive Economics
PureTech highlights a history of creating monetization events and non‑dilutive economics: three FDA‑approved therapeutics originating from its engine (including Cobenfy), over $1 billion generated from monetization of founded‑entity economics historically, and approximately $125M received to date from a prior Cobenfy royalty sale. Analyst consensus projects ~ $160M of value from Cobenfy economics through 2033 (management notes sensitivity).
Seaport Progress — IPO Filing and Clinical Development
Seaport advanced two clinical trials for neuropsychiatric conditions (2025 and 2026) and filed a registration statement for a potential Nasdaq IPO. This progress is presented as validation of the hub‑and‑spoke model and the ability to create scaleable, stand‑alone biotech companies.
Focused Innovation Cadence (Candidate Targets)
Management plans to progress up to three concept‑stage programs and nominate up to two development candidates over the next three years (Cadence: up to two development candidates over a 3‑year period), emphasizing capital‑efficient early derisking and a focus on areas of historic strength (e.g., CNS).
Corporate Simplification to Reduce Costs
Announced intention to voluntarily delist from Nasdaq and retain primary LSE listing to simplify structure, reduce administrative burden and lower costs, consistent with a plan to run a significantly leaner hub post‑fundraise.
PRTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $18.14 | $17.40 | -4.08% |
Aug 28, 2025 | $18.01 | $17.35 | -3.66% |
Apr 30, 2025 | $17.50 | $17.26 | -1.37% |
Aug 28, 2024 | $25.00 | $23.50 | -6.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PureTech Health (PRTC) report earnings?
PureTech Health (PRTC) is schdueled to report earning on Aug 27, 2026, TBA (Confirmed).
What is PureTech Health (PRTC) earnings time?
PureTech Health (PRTC) earnings time is at Aug 27, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRTC EPS forecast?
Currently, no data Available